Pipeline
Atopic dermatitisAs atopic dermatitis has so many causes that it is very difficult to treat accurately, the main focus is on alleviating symptoms and preventing recurrence as its treatments. Although many drugs have been developed to date, there is no fundamental treatment, and with many side effects, resulting in strong unmet needs for the development of atopic dermatitis drugs.
Restoration of the vascular barrierAvixgen's AVI-3307, a new drug candidate for the treatment of atopic dermatitis, normalizes excessively increased vascular permeability caused from atopic dermatitis by suppressing angiogenesis formation and restoring proteins in the damaged vascular barrier, thereby inhibiting the plasma leakage and the migration of inflammatory cells to the tissue of atopic skin. This ensures a differentiated mechanism of action that can block excessive skin inflammatory reactions and provide a fundamental treatment for atopic patients at all levels.
Effects of alternative and combined treatmentsIn the current situation where there are only drugs with extreme side effects, such as steroids, etc., it is expected to play a role as an alternative drug and to maximize the therapeutic effects through combined treatments because it has a different mechanism from that of other existing drugs.
